Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.

Rieder F, Siegmund B, Bundschuh DS, Lehr HA, Endres S, Eigler A.

PLoS One. 2013;8(2):e56867. doi: 10.1371/journal.pone.0056867. Epub 2013 Feb 28.

2.

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.

Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups.

Lancet. 2009 Aug 29;374(9691):695-703. doi: 10.1016/S0140-6736(09)61252-6.

PMID:
19716961
3.

Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.

Wollin L, Bundschuh DS, Wohlsen A, Marx D, Beume R.

Pulm Pharmacol Ther. 2006;19(5):343-52. Epub 2005 Oct 28.

PMID:
16257550
4.

Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma.

Belvisi MG, Bundschuh DS, Stoeck M, Wicks S, Underwood S, Battram CH, Haddad el-B, Webber SE, Foster ML.

J Pharmacol Exp Ther. 2005 Aug;314(2):568-74. Epub 2005 May 5.

PMID:
15878996
5.

In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide.

Stoeck M, Riedel R, Hochhaus G, Häfner D, Masso JM, Schmidt B, Hatzelmann A, Marx D, Bundschuh DS.

J Pharmacol Exp Ther. 2004 Apr;309(1):249-58. Epub 2004 Jan 12.

PMID:
14718604
6.

In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.

Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R.

J Pharmacol Exp Ther. 2001 Apr;297(1):280-90.

PMID:
11259555
7.
8.

Temporal sequence of pulmonary and systemic inflammatory responses to graded polymicrobial peritonitis in mice.

Stamme C, Bundschuh DS, Hartung T, Gebert U, Wollin L, Nüsing R, Wendel A, Uhlig S.

Infect Immun. 1999 Nov;67(11):5642-50.

9.

In vitro prevention and reversal of lipopolysaccharide desensitization by IFN-gamma, IL-12, and granulocyte-macrophage colony-stimulating factor.

Randow F, Döcke WD, Bundschuh DS, Hartung T, Wendel A, Volk HD.

J Immunol. 1997 Mar 15;158(6):2911-8.

PMID:
9058829
10.

Granulocyte-macrophage colony-stimulating factor and IFN-gamma restore the systemic TNF-alpha response to endotoxin in lipopolysaccharide-desensitized mice.

Bundschuh DS, Barsig J, Hartung T, Randow F, Döcke WD, Volk HD, Wendel A.

J Immunol. 1997 Mar 15;158(6):2862-71.

PMID:
9058823
11.

Isolation of rat primary lung cells: characterization of an improved method.

Bundschuh DS, Uhlig S, Wendel A.

Exp Toxicol Pathol. 1996 Nov;48(6):512-4.

PMID:
8954335
12.

Control of fecal peritoneal infection in mice by colony-stimulating factors.

Barsig J, Bundschuh DS, Hartung T, Bauhofer A, Sauer A, Wendel A.

J Infect Dis. 1996 Oct;174(4):790-9.

PMID:
8843218
13.

Isolation and characterization of rat primary lung cells.

Bundschuh DS, Uhlig S, Leist M, Sauer A, Wendel A.

In Vitro Cell Dev Biol Anim. 1995 Oct;31(9):684-91.

PMID:
8564079
14.

Induction of hepatic Ito cell nitric oxide production after acute endotoxemia.

Helyar L, Bundschuh DS, Laskin JD, Laskin DL.

Hepatology. 1994 Dec;20(6):1509-15.

PMID:
7527004

Supplemental Content

Loading ...
Support Center